{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:09Z","timestamp":1790239389420,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Describe the original mechanism of action of ET-743.Explain the management of patients treated with ET-743, including what biological exams are needed because of toxicity and what is the optimal schedule of administration.Choose the best histological subtype of sarcoma for treatment with ET-743 and describe the clinical aim of treatment.Discuss putative combinations of ET-743 with other therapies.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>Ecteinascidin-743 (ET-743) is a natural product derived from the marine tunicate Ectenascidia turbinate. ET-743 binds in the minor groove of DNA, blocks transcription factors activity, and traps protein from the nucleotide excision repair system, thus blocking cells in G2-M phase. ET-743 demonstrated cytotoxic activity at very low concentrations against sarcoma cell lines in pre-clinical studies. In several phase II clinical studies in patients with advanced sarcoma failing conventional doxorubicin- and ifosfamide-based chemotherapy, ET-743 delivered by continuous intravenous 24-hour infusion at a dose of 1,500 \u03bcg\/m2 every 21 days yielded 8% overall response and 30%\u201340% stabilization rates for a clinical benefit rate close to 40%. Interestingly, long-term stabilizations over more than 3 years have been described. In vivo, ET-743 has a specific toxicity profile, the major toxicity of this product being hepatic, through biliary duct destruction, and hematologic. ET-743 has also been evaluated in first-line treatment for these patients. Finally, due to its original mode of action and the lack of cross-resistance with other chemotherapy agents, ET-743 was tested in a preclinical model in combination with other drugs. Synergy was reported in vitro with doxorubicin and cisplatin; phase I combination studies are in progress.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.10-10-827","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T22:43:54Z","timestamp":1132785834000},"page":"827-832","source":"Crossref","is-referenced-by-count":32,"title":["ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas"],"prefix":"10.1093","volume":"10","author":[{"given":"J\u00e9r\u00f4me","family":"Fayette","sequence":"first","affiliation":[{"name":"H\u00f4pital Edouard Herriot, Medical Oncology Department, Lyon, France"},{"name":"INSERM U590, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Ray","family":"Coquard","sequence":"additional","affiliation":[{"name":"H\u00f4pital Edouard Herriot, Medical Oncology Department, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alberti","sequence":"additional","affiliation":[{"name":"H\u00f4pital Edouard Herriot, Medical Oncology Department, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Ranch\u00e8re","sequence":"additional","affiliation":[{"name":"H\u00f4pital Edouard Herriot, Medical Oncology Department, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Boyle","sequence":"additional","affiliation":[{"name":"H\u00f4pital Edouard Herriot, Medical Oncology Department, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"H\u00f4pital Edouard Herriot, Medical Oncology Department, Lyon, France"},{"name":"INSERM U590, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,11,1]]},"reference":[{"key":"2021122209520383800_R1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122209520383800_R2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0959-8049(02)00480-X","article-title":"Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy","volume":"39","author":"Blay","year":"2003","journal-title":"Eur J Cancer"},{"key":"2021122209520383800_R3","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/bi960306b","article-title":"DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata","volume":"35","author":"Pommier","year":"1996","journal-title":"Biochemistry"},{"key":"2021122209520383800_R4","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1021\/jm990241l","article-title":"Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove","volume":"42","author":"Zewail-Foote","year":"1999","journal-title":"J Med Chem"},{"key":"2021122209520383800_R5","first-page":"179","article-title":"Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA","volume":"14","author":"Bonfanti","year":"1999","journal-title":"Anticancer Drug Des"},{"key":"2021122209520383800_R6","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1073\/pnas.97.12.6780","article-title":"Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743","volume":"97","author":"Minuzzo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122209520383800_R7","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1073\/pnas.97.12.6775","article-title":"Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation","volume":"97","author":"Jin","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122209520383800_R8","first-page":"1327","article-title":"Overcoming multidrug drug resistance in P-glycoprotein\/MDR1-overexpressing cell lines by ecteinascidin 743","volume":"1","author":"Kanzaki","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"2021122209520383800_R9","first-page":"3377","article-title":"Ecteinascidin-743 inhibits activated but not constitutive transcription","volume":"62","author":"Friedman","year":"2002","journal-title":"Cancer Res"},{"key":"2021122209520383800_R10","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.1073\/pnas.96.13.7196","article-title":"Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove","volume":"96","author":"Takebayashi","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122209520383800_R11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.1221","article-title":"Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways","volume":"92","author":"Damia","year":"2001","journal-title":"Int J Cancer"},{"key":"2021122209520383800_R12","first-page":"185","article-title":"Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122209520383800_R13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","article-title":"Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action","volume":"37","author":"Erba","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122209520383800_R14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"key":"2021122209520383800_R15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1074-5521(01)00071-0","article-title":"The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent","volume":"8","author":"Zewail-Foote","year":"2001","journal-title":"Chem Biol"},{"key":"2021122209520383800_R16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bcp.2005.04.013","article-title":"Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways","volume":"70","author":"Soares","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"2021122209520383800_R17","first-page":"2908","article-title":"Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent","volume":"7","author":"Li","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122209520383800_R18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/mol.63.3.632","article-title":"Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells","volume":"63","author":"Biroccio","year":"2003","journal-title":"Mol Pharmacol"},{"key":"2021122209520383800_R19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejca.2004.10.021","article-title":"Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743","volume":"41","author":"Marchini","year":"2005","journal-title":"Eur J Cancer"},{"key":"2021122209520383800_R20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1158\/1535-7163.MCT-04-0316","article-title":"Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemonaive patients","volume":"4","author":"Martinez","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"2021122209520383800_R21","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.bcp.2003.08.033","article-title":"Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations","volume":"66","author":"Shao","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"2021122209520383800_R22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209520383800_R23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ejca.2004.02.005","article-title":"A phase II study of ET-743\/trabectedin (\u2018Yondelis\u2019) for patients with advanced gastrointestinal stromal tumours","volume":"40","author":"Blay","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122209520383800_R24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","article-title":"Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial","volume":"23","author":"Le Cesne","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209520383800_R25","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209520383800_R26","first-page":"9027a","article-title":"Tumor control and objective responses: single-center experience with Ecteinascidin-743 (ET-743, Yondelis), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas","volume":"23","author":"Sch\u00f6ffski","year":"2005","journal-title":"Proc ASCO"},{"key":"2021122209520383800_R27","first-page":"4256","article-title":"Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat","volume":"62","author":"Donald","year":"2002","journal-title":"Cancer Res"},{"key":"2021122209520383800_R28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-002-0498-3","article-title":"Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity","volume":"50","author":"Puchalski","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122209520383800_R29","first-page":"5902","article-title":"Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat","volume":"63","author":"Donald","year":"2003","journal-title":"Cancer Res"},{"key":"2021122209520383800_R30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-003-0744-3","article-title":"Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro","volume":"53","author":"Donald","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122209520383800_R31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ijc.20356","article-title":"Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma","volume":"111","author":"Donald","year":"2004","journal-title":"Int J Cancer"},{"key":"2021122209520383800_R32","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0959-8049(01)00245-3","article-title":"In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results","volume":"38","author":"Albella","year":"2002","journal-title":"Eur J Cancer"},{"key":"2021122209520383800_R33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.exphem.2003.07.004","article-title":"In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells","volume":"31","author":"Gomez","year":"2003","journal-title":"Exp Hematol"},{"key":"2021122209520383800_R34","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1158\/0008-5472.CAN-04-4037","article-title":"Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production","volume":"65","author":"Allavena","year":"2005","journal-title":"Cancer Res"},{"key":"2021122209520383800_R35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209520383800_R36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"key":"2021122209520383800_R37","first-page":"9000a","article-title":"Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy","volume":"22","author":"Samuels","year":"2004","journal-title":"Proc ASCO"},{"key":"2021122209520383800_R38","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.11563","article-title":"Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma","volume":"98","author":"Laverdiere","year":"2003","journal-title":"Cancer"},{"key":"2021122209520383800_R39","first-page":"3893","article-title":"Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells","volume":"8","author":"Scotlandi","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2021122209520383800_R40","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/S0959-8049(03)00490-8","article-title":"The combination of yondelis and cisplatin is synergistic against human tumor xenografts","volume":"39","author":"D'Incalci","year":"2003","journal-title":"Eur J Cancer"},{"key":"2021122209520383800_R41","first-page":"542a","article-title":"Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors","volume":"22","author":"Grasselli","year":"2003","journal-title":"Proc ASCO"},{"key":"2021122209520383800_R42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-003-0636-6","article-title":"Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies","volume":"52","author":"Meco","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122209520383800_R43","first-page":"3251","article-title":"Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells","volume":"7","author":"Takahashi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122209520383800_R44","first-page":"1211","article-title":"Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis","volume":"9","author":"Morioka","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122209520383800_R45","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1038\/sj.bjc.6601431","article-title":"In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects","volume":"89","author":"Simoens","year":"2003","journal-title":"Br J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.10-10-827","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.10-10-827","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/10\/10\/827\/41852467\/oncolo_10_10_827.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/10\/10\/827\/41852467\/oncolo_10_10_827.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:47:20Z","timestamp":1640195240000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/10\/10\/827\/6387367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,11,1]]},"published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.10-10-827","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,11,1]]},"published":{"date-parts":[[2005,11,1]]}}}